Abstract Policy and Regulations
With the submission of an abstract to ECCO2017 European Cancer Congress, the presenting author:
PRINT THIS PAGE
Page last modified:
- Certifies to be an investigator with substantial involvement in the clinical study presented in the abstract.
- Accepts responsibility for the accuracy of the submitted abstract.
- Accepts to be the contact person for all correspondence regarding the abstract and inform co-authors of its status.
- Confirms that all co-authors are aware of and agree to the content of the abstract and support the data presented.
- Agrees to submit updated data for important large studies presented (in part) at previous meetings.
- Certifies that the information in the abstract is for exclusive presentation in the ECCO2017 European Cancer Congress Scientific Programme and will not be presented during the ECCO2017 at any Satellite Symposia.
- States that for all studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and informed consent given where appropriate.
- For abstracts containing clinical trial data include: Trial abbreviation; Trial Registry Number or ID background; Objective, Design, Population studied (including sample size), Intervention, Outcome measure (s), Analysis, Trial status, Trial sponsor(s)
- Identifies, obtains and discloses any financial interest in products or processes described in the abstract for all abstract authors. This includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research and other substantive relationships.
- Releases the copyright on behalf of all authors, to ECCO and gives permission for the abstract, when selected for presentation, to be published in the ECCO2017 European Cancer Congress Abstract book - a European Journal of Cancer Supplement (in electronic format), as well as on the ECCO2017 website.
- Encore abstracts will be accepted.